RNS Number : 4851L
Shield Therapeutics PLC
06 September 2023

Shield Therapeutics plc
("Shield" or the "Company" or the "Group")

Notice of interim results
Change in reporting currency

London, UK, 6 September 2023: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company focused on the commercialisation of its innovative oral iron therapy for iron deficiency, Accrufer®/Feraccru® (ferric maltol), will announce its interim results for the six months ended 30 June 2023 on Thursday 28 September 2023.

Investor presentation

CEO, Greg Madison, and CFO, Hans-Peter Rudolf, will be hosting a live online presentation relating to the interim results via the Investor Meet Company platform at 16.30 (BST) on Thursday 28 September 2023.

The presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 09:00 (BST) the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Shield Therapeutics plc via:

https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor

Investors who already follow Shield Therapeutics plc on the Investor Meet Company platform will automatically be invited.

Change in reporting currency

Reflecting the increasing importance of the Group's U.S. operations on its financial results, Shield is also announcing that it will change its reporting currency from Pounds Sterling to US Dollars (USD) effective 1 January 2023.The interim results for the six months ending 30 June 2023 will include condensed, consolidated USD financial information for H123 and FY22. In accordance with the relevant accounting standards, comparative historic financial information for FY 2022 will be published in USD alongside the full FY 2023 results in the first half of 2024.

For further information please contact:

Shield Therapeutics plc www.shieldtherapeutics.com
Greg Madison, CEO +44 (0) 191 511 8500
Hans-Peter Rudolf, CFO

Nominated Adviser and Joint Broker
Peel Hunt LLP
James Steel/Patrick Birkholm +44 (0)20 7418 8900

Joint Broker
finnCap Ltd
+44 (0)20 7220 0500

Geoff Nash/ George Dollemore /Nigel Birks/Harriet Ward

Financial PR & IR Advisor
Walbrook PR
Paul McManus/Lianne Applegarth/ Alice Woodings
+44 (0)20 7933 8780 or shield@walbrookpr.com

Investor Contact (US Advisor)
LifeSci Advisors, LLC
John Mullaly
+1 617 429 3548 or jmullaly@lifesciadvisors.com

About Accrufer®/Feraccru®

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of action compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com

About Shield Therapeutics plc

Shield is a commercial stage pharmaceutical company focused on the commercialisation of Accrufer®/Feraccru® (ferric maltol), an innovative oral iron therapy for iron deficiency differentiated from other irons by its efficacy, broad label and well-tolerated formulation. The Group has launched Accrufer® in the US with an exclusive, multi-year collaboration agreement with Viatris, Inc. Feraccru® is commercialised in the UK and European Union by Norgine B.V., that also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.
Accrufer®/Feraccru® has patent coverage until the mid-2030s
Accrufer®/Feraccru® are registered trademarks of the Shield Group

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOREAFNSEEADEAA